ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update
ThermoGenesis Holdings, Inc. (Nasdaq: THMO) will release its financial results for the second quarter ended June 30, 2022, on August 11, 2022. A corporate strategic update will accompany the results, followed by a conference call at 12:00 p.m. PT. Investors can participate via phone or webcast. The company specializes in automated technologies for CAR-T and other cell-based therapies, offering solutions for clinical biobanking and immuno-oncology.
- ThermoGenesis is a leader in automated cell processing, indicating strong market positioning.
- The upcoming financial results and strategic update may reveal potential growth opportunities.
- None.
Conference Call to be Held on August 11, 2022
RANCHO CORDOVA, Calif., Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022. A conference call and webcast will follow at 12:00 p.m. PT/ 3:00 p.m. ET.
To participate in the conference call, please dial 1-844-889-4331 (domestic), 1-412-380-7406 (international) or 1-866-605-3852 (Canada). To access a live webcast of the call, please visit: https://thermogenesis.com/investors/news-and-events/events-webcasts/.
A webcast replay will be available on ThermoGenesis' website for three months by visiting the Investor page of the Company's website at www.thermogenesis.com.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.
Company Contact:
Wendy Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-announce-financial-results-for-the-second-quarter-ended-june-30-2022-and-provide-a-corporate-strategic-update-301602796.html
SOURCE ThermoGenesis Holdings, Inc.
FAQ
When will ThermoGenesis Holdings announce its second quarter financial results?
What is the ticker symbol for ThermoGenesis Holdings?
What time is the conference call for ThermoGenesis Holdings?
What technologies does ThermoGenesis Holdings develop?
